Efficacy and tolerability of vildagliptin in type 2 diabetic patients on hemodialysis.
Anti-diabetic agent-related hypoglycemia is a serious complication in type 2 diabetic patients on hemodialysis. Therefore, we assessed the efficacy and tolerability of 24 weeks of monotherapy with vildagliptin, a dipeptidyl peptidase four inhibitor, which is a new class of antidiabetic agent. This open-label, single-arm clinical trial was performed on 26 patients on hemodialysis. The primary assessments were changes in postprandial glucose level and glycated albumin (GA). During the study, three patients dropped out, and data from 23 patients were analyzed. Significant reductions were seen in postprandial glucose (-2.60 ± 3.80 mmol/L, P < 0.001) and GA (-2.59 ± 2.33%, P < 0.001) levels. No serious drug-related adverse events were observed. Vildagliptin monotherapy can be recommended for glycemic control in type 2 diabetic patients on hemodialysis. This trial was registered with the University Hospital Medical Information Network (no. UMIN000003661). (J Diabetes Invest, doi: 10.1111/j.2040-1124.2011.00169.x, 2011).
Department of Medicine, Shiga University of Medical Science, Otsu, Shiga.
Shinji
S
Kume
Department of Medicine, Shiga University of Medical Science, Otsu, Shiga.
Takashi
T
Uzu
Rakuwakai Otowa Memorial Hospital, Yamashina, Kyoto.
Chieko
C
Takagi
Rakuwakai Otowa Memorial Hospital, Yamashina, Kyoto.
Morihiro
M
Kondo
Rakuwakai Otowa Memorial Hospital, Yamashina, Kyoto.
Tomoko
T
Okabe
Department of Medicine, Shiga University of Medical Science, Otsu, Shiga.
Shin-Ichi
S
Araki
Department of Medicine, Shiga University of Medical Science, Otsu, Shiga.
Keiji
K
Isshiki
Department of Medicine, Shiga University of Medical Science, Otsu, Shiga.
Naoko
N
Takeda
Department of Medicine, Shiga University of Medical Science, Otsu, Shiga.
Keiko
K
Kondo
Department of Medicine, Asahikawa Medical College, Asahikawa, Hokkaido.
Masakazu
M
Haneda
Division of Diabetes & Endocrinology, Kanazawa Medical University, Kahoku-Gun, Ishikawa, Japan.
Daisuke
D
Koya
Department of Medicine, Shiga University of Medical Science, Otsu, Shiga.
Yoshihiko
Y
Nishio
Department of Medicine, Shiga University of Medical Science, Otsu, Shiga.
Atsunori
A
Kashiwagi
Department of Medicine, Shiga University of Medical Science, Otsu, Shiga.
Hiroshi
H
Maegawa
DPP‐4; Hemodialysis; Vildagliptin